Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.69 |
| ▸ | PDE4A | P27815 | 6/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074719 | 1.00 | PDE4D (0.69) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL4701160 | 0.88 | PDE4A (0.72) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL4698806 | 0.85 | PDE4A (0.69) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL4701218 | 0.82 | PDE4D (0.78) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL4699020 | 0.81 | PDE4A (0.76) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL4697930 | 0.81 | PDE4A (0.70) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL155477 | 0.79 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL92611 | 0.79 | PDE4A (0.71) | PDE4DPDE4APDE4BPDE4CIRAK4 | |
| SCHEMBL4702946 | 0.79 | PDE4A (0.67) | PDE4DPDE4APDE4BPDE4CHTT | |
| SCHEMBL4701482 | 0.78 | KDM4E (0.71) | PDE4DPDE4APDE4BPDE4CHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | MERCK SERONO SA (CH) | 2008-11-27 | — | — | US | claimed |
| EP-0952832-B1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LTD (GB) | 2008-08-27 | — | — | EP | claimed |
| US-20050277648-A1 | Use of PDE IV inhibitors to treat angiogenesis | ALCON RESEARCH, LTD. | 2005-12-15 | — | — | US | claimed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | claimed |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | MERCK SERONO SA (CH) | 2005-07-07 | — | — | US | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250109110-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2023146892-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | PARION SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-0952832-A1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | Darwin Discovery Limited (GB) | 1999-11-03 | — | — | EP | disclosed |
| WO-1997044036-A1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | PDE4D 565/4885PDE4A 455/4885PDE4B 330/4885 |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | PDE4A, PDE4B, PDE4C | PDE4D 8/4885PDE4A 1/4885PDE4B 2/4885 |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | CFTR, ELANE, IL5 | PDE4D 182/4885PDE4A 231/4885PDE4B 186/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | PDE4D 2296/4885PDE4A 1695/4885PDE4B 1544/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | PDE4D 8/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | PDE4A, PDE4B, PDE4C | PDE4D 8/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20250109110-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | PDE4D 332/4885PDE4A 285/4885PDE4B 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.